Building strong bones later in life certainly has a value to every aging American, but taking drugs aimed at fighting osteoporosis might actually lower a woman's risk of developing breast cancer as well, new research indicates.
A recent study, published in the British Journal of Cancer, found that women who used bisphosphonate drugs, such as Fosamax, Boniva and Zometa, for longer than two years faced a 40 percent lower risk of developing breast cancer than their counterparts, the Seattle Post Intelligencer reports.
Researchers at the Fred Hutchinson Cancer Research Center's cancer prevention program examined 6,000 women between the ages of 20 and 69, and found that osteoporosis-fighting drugs likely had some role in preventing tumors from gaining a blood supply.
Polly Newcomb, the study's lead author, succinctly told the news source, "This large study provides new evidence that the use of bisphosphonates is associated with a potentially important reduction in breast-cancer risk."
While most women begin experiencing bone loss after age 50, experts at the American Cancer Society recommend that women as young as 20 begin making breast cancer screening a part of their health routine.